MDM2 and cancer: Given that SL candidates NDUFB5 in the STAD screen; MDM2 and TUBA1B in the COAD/READ screen; and WRN in the COAD/READ and pan-cancer screens were identified as the most promising therapeutic targets (priority class A) for KMT2DLOF cancers, we sought to understand the relationship between KMT2D and these genes further.